KineMed Extends Collaboration With Bristol-Myers Squibb

KineMed, Inc. announced today the extension of its collaboration with Bristol-Myers Squibb BMY in the area of Alzheimer's disease and other neurodegenerative conditions.

Under the terms of the extension, Bristol-Myers Squibb has non-exclusively licensed KineMed's technologies to identify and characterize biomarkers for Alzheimer's disease in cerebrospinal fluid.